Theravance Biopharma and Mylan report positive new data from multiple studies of YUPELRI™
Theravance Biopharma and Mylan announced that positive new data from multiple studies of YUPELRI™ (revefenacin) inhalation solution. YUPELRI is an investigational long-acting muscarinic antagonist currently under review by the FDA for the treatment of COPD. The PDUFA date is Nov. 13, 2018. October 11, 2018